Nello Mainolfi Sells 30,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $78.06, for a total value of $2,341,800.00. Following the completion of the transaction, the chief executive officer directly owned 663,077 shares of the company’s stock, valued at approximately $51,759,790.62. The trade was a 4.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Nello Mainolfi also recently made the following trade(s):

• On Monday, December 8th, Nello Mainolfi sold 100,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.17, for a total value of $8,917,000.00.
• On Wednesday, October 29th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $60.99, for a total transaction of $1,829,700.00.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $77.81 on Friday. The company’s 50-day simple moving average is $71.31 and its 200-day simple moving average is $55.77. Kymera Therapeutics, Inc. has a fifty-two week low of $19.44 and a fifty-two week high of $103.00. The stock has a market capitalization of $5.60 billion, a P/E ratio of -21.67 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.19). The firm had revenue of $2.76 million for the quarter, compared to the consensus estimate of $23.15 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%. On average, research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Institutional Trading of Kymera Therapeutics

Several large investors have recently made changes to their positions in the business. Hudson Bay Capital Management LP raised its holdings in shares of Kymera Therapeutics by 362.7% during the third quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company’s stock worth $1,309,000 after purchasing an additional 18,134 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Kymera Therapeutics during the 3rd quarter worth about $304,000. Dark Forest Capital Management LP raised its stake in shares of Kymera Therapeutics by 19.7% during the 3rd quarter. Dark Forest Capital Management LP now owns 31,052 shares of the company’s stock valued at $1,758,000 after buying an additional 5,102 shares during the last quarter. Alyeska Investment Group L.P. lifted its holdings in shares of Kymera Therapeutics by 1,130.2% in the 3rd quarter. Alyeska Investment Group L.P. now owns 615,091 shares of the company’s stock valued at $34,814,000 after buying an additional 565,091 shares during the period. Finally, Verition Fund Management LLC boosted its stake in shares of Kymera Therapeutics by 270.9% in the third quarter. Verition Fund Management LLC now owns 31,471 shares of the company’s stock worth $1,781,000 after buying an additional 22,987 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on KYMR. Piper Sandler restated an “overweight” rating and set a $125.00 target price (up from $98.00) on shares of Kymera Therapeutics in a research note on Tuesday, December 9th. Stephens boosted their price target on Kymera Therapeutics from $65.00 to $110.00 and gave the stock an “overweight” rating in a research note on Thursday, December 11th. Morgan Stanley upped their price objective on shares of Kymera Therapeutics from $73.00 to $127.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th. JPMorgan Chase & Co. lifted their target price on shares of Kymera Therapeutics from $70.00 to $125.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $116.30.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.